BACKGROUND: Whereas propionic acidemia (PA) is a target disease of newborn screening (NBS) in many countries, it is not in others. Data on the benefit of NBS for PA are sparse. STUDY DESIGN: Twenty PA patients diagnosed through NBS were compared to 35 patients diagnosed by selective metabolic screening (SMS) prompted by clinical findings, family history, or routine laboratory test results. Clinical and biochemical data of patients from 16 metabolic centers in Germany, Austria, and Switzerland were evaluated retrospectively. Additionally, assessment of the intelligent quotient (IQ) was performed. In a second step, the number of PA patients who have died within the past 20 years was estimated based on information provided by the participating metabolic centers. RESULTS: Patients diagnosed through NBS had neither a milder clinical course regarding the number of metabolic crises nor a better neurological outcome. Among NBS patients, 63% were already symptomatic at the time of diagnosis, and <10% of all patients remained asymptomatic. Among all PA patients, 76% were found to be at least mildly mentally retarded, with an IQ <69. IQ was negatively correlated with the number of metabolic decompensations, but not simply with the patients' age. Physical development was also impaired in the majority of patients. Mortality rates tended to be lower in NBS patients compared with patients diagnosed by SMS. CONCLUSION: Early diagnosis of PA through NBS seems to be associated with a lower mortality rate. However, no significant benefit could be shown for surviving patients with regard to their clinical course, including the number of metabolic crises, physical and neurocognitive development, and long-term complications.
BACKGROUND: Whereas propionic acidemia (PA) is a target disease of newborn screening (NBS) in many countries, it is not in others. Data on the benefit of NBS for PA are sparse. STUDY DESIGN: Twenty PA patients diagnosed through NBS were compared to 35 patients diagnosed by selective metabolic screening (SMS) prompted by clinical findings, family history, or routine laboratory test results. Clinical and biochemical data of patients from 16 metabolic centers in Germany, Austria, and Switzerland were evaluated retrospectively. Additionally, assessment of the intelligent quotient (IQ) was performed. In a second step, the number of PA patients who have died within the past 20 years was estimated based on information provided by the participating metabolic centers. RESULTS:Patients diagnosed through NBS had neither a milder clinical course regarding the number of metabolic crises nor a better neurological outcome. Among NBSpatients, 63% were already symptomatic at the time of diagnosis, and <10% of all patients remained asymptomatic. Among all PA patients, 76% were found to be at least mildly mentally retarded, with an IQ <69. IQ was negatively correlated with the number of metabolic decompensations, but not simply with the patients' age. Physical development was also impaired in the majority of patients. Mortality rates tended to be lower in NBSpatients compared with patients diagnosed by SMS. CONCLUSION: Early diagnosis of PA through NBS seems to be associated with a lower mortality rate. However, no significant benefit could be shown for surviving patients with regard to their clinical course, including the number of metabolic crises, physical and neurocognitive development, and long-term complications.
Authors: S Kölker; E Christensen; J V Leonard; C R Greenberg; A B Burlina; A P Burlina; M Dixon; M Duran; S I Goodman; D M Koeller; E Müller; E R Naughten; E Neumaier-Probst; J G Okun; M Kyllerman; R A Surtees; B Wilcken; G F Hoffmann; P Burgard Journal: J Inherit Metab Dis Date: 2007-01-03 Impact factor: 4.982
Authors: S B van der Meer; F Poggi; M Spada; J P Bonnefont; H Ogier; P Hubert; E Depondt; D Rapoport; D Rabier; C Charpentier; P Parvy; J Bardet; P Kamoun; J M Saudubray Journal: Eur J Pediatr Date: 1996-03 Impact factor: 3.183
Authors: T Yorifuji; M Kawai; M Mamada; K Kurokawa; H Egawa; Y Shigematsu; Y Kohno; K Tanaka; T Nakahata Journal: J Inherit Metab Dis Date: 2004 Impact factor: 4.982
Authors: M Rela; N Battula; M Madanur; G Mieli-Vergani; A Dhawan; M Champion; J Raiman; N Heaton Journal: Am J Transplant Date: 2007-09 Impact factor: 8.086
Authors: J P Kraus; E Spector; S Venezia; P Estes; P W Chiang; G Creadon-Swindell; S Müllerleile; L de Silva; M Barth; M Walter; K Walter; T Meissner; M Lindner; R Ensenauer; R Santer; O A Bodamer; M R Baumgartner; M Brunner-Krainz; D Karall; C Haase; I Knerr; T Marquardt; J B Hennermann; R Steinfeld; S Beblo; H G Koch; V Konstantopoulou; S Scholl-Bürgi; A van Teeffelen-Heithoff; T Suormala; M Ugarte; W Sperl; A Superti-Furga; K O Schwab; S C Grünert; J O Sass Journal: J Inherit Metab Dis Date: 2011-10-27 Impact factor: 4.982
Authors: Jana Heringer; Vassili Valayannopoulos; Allan M Lund; Frits A Wijburg; Peter Freisinger; Ivo Barić; Matthias R Baumgartner; Peter Burgard; Alberto B Burlina; Kimberly A Chapman; Elisenda Cortès I Saladelafont; Daniela Karall; Chris Mühlhausen; Victoria Riches; Manuel Schiff; Jolanta Sykut-Cegielska; John H Walter; Jiri Zeman; Brigitte Chabrol; Stefan Kölker Journal: J Inherit Metab Dis Date: 2015-12-21 Impact factor: 4.982
Authors: Roland Posset; Stefan Kölker; Florian Gleich; Jürgen G Okun; Andrea L Gropman; Sandesh C S Nagamani; Svenja Scharre; Joris Probst; Magdalena E Walter; Georg F Hoffmann; Sven F Garbade; Matthias Zielonka Journal: Mol Genet Metab Date: 2020-11-07 Impact factor: 4.797
Authors: Nicholas M McCrory; Mathew J Edick; Ayesha Ahmad; Susan Lipinski; Jessica A Scott Schwoerer; Shaohui Zhai; Kaitlin Justice; Cynthia A Cameron; Susan A Berry; Loren D M Pena Journal: J Pediatr Date: 2016-10-21 Impact factor: 4.406
Authors: Gerarda Cappuccio; Paldeep S Atwal; Taraka R Donti; Kiki Ugarte; Nadia Merchant; William J Craigen; V Reid Sutton; Sarah H Elsea Journal: JIMD Rep Date: 2016-11-30